Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs
Author
Abstract
Suggested Citation
Note: DOI: 10.1257/aer.p20171086
Download full text from publisher
Other versions of this item:
- Margaret Kyle & Heidi L. Williams, 2017. "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," NBER Working Papers 23068, National Bureau of Economic Research, Inc.
- Margaret Kyle & Heidi Williams, 2016. "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," Post-Print hal-01448505, HAL.
- Margaret Kyle & Heidi Williams, 2017. "Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs," Post-Print hal-01952720, HAL.
References listed on IDEAS
- Margaret Kyle & Yi Qian, 2014.
"Intellectual Property Rights and Access to Innovation: Evidence from TRIPS,"
NBER Working Papers
20799, National Bureau of Economic Research, Inc.
- Margaret Kyle, 2016. "Intellectual Property Rights and Access to Innovation: Evidence from TRIPS," Working Papers hal-01448524, HAL.
- Margaret Kyle & Qian Yi, 2014. "Intellectual property rights and access to innovation: evidence from TRIPS," Working Papers hal-01952690, HAL.
- Alan M. Garber & Jonathan Skinner, 2008.
"Is American Health Care Uniquely Inefficient?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(4), pages 27-50, Fall.
- Alan M. Garber & Jonathan Skinner, 2008. "Is American Health Care Uniquely Inefficient?," NBER Working Papers 14257, National Bureau of Economic Research, Inc.
- Margaret K. Kyle, 2007. "Pharmaceutical Price Controls and Entry Strategies," The Review of Economics and Statistics, MIT Press, vol. 89(1), pages 88-99, February.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Otilia Boldea & Bettina Drepper & Zhuojiong Gan, 2020.
"Change point estimation in panel data with time‐varying individual effects,"
Journal of Applied Econometrics, John Wiley & Sons, Ltd., vol. 35(6), pages 712-727, September.
- Otilia Boldea & Bettina Drepper & Zhuojiong Gan, 2018. "Change Point Estimation in Panel Data with Time-Varying Individual Effects," Papers 1808.03109, arXiv.org.
- Margaret K. Kyle, 2018.
"Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets,"
Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
- Margaret Kyle, 2016. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Working Papers hal-01448521, HAL.
- Margaret Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Post-Print hal-01952663, HAL.
- Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.
- Margaret Kyle, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Working Papers hal-01952727, HAL.
- Joshua Krieger & Danielle Li & Dimitris Papanikolaou, 2022.
"Missing Novelty in Drug Development,"
The Review of Financial Studies, Society for Financial Studies, vol. 35(2), pages 636-679.
- Joshua L. Krieger & Danielle Li & Dimitris Papanikolaou, 2018. "Missing Novelty in Drug Development," NBER Working Papers 24595, National Bureau of Economic Research, Inc.
- Madhu Mazumdar & Jashvant V. Poeran & Bart S. Ferket & Nicole Zubizarreta & Parul Agarwal & Ksenia Gorbenko & Catherine K. Craven & Xiaobo (Tony) Zhong & Alan J. Moskowitz & Annetine C. Gelijns & Davi, 2021. "Developing an Institute for Health Care Delivery Science: successes, challenges, and solutions in the first five years," Health Care Management Science, Springer, vol. 24(1), pages 234-243, March.
- Kyle, Margaret K., 2022.
"Incentives for pharmaceutical innovation: What’s working, what’s lacking,"
International Journal of Industrial Organization, Elsevier, vol. 84(C).
- Margaret Kyle, 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," Post-Print hal-03935839, HAL.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Nebibe Varol & Joan Costa-Font & Alistair McGuire, 2012.
"Do International Launch Strategies of Pharmaceutical Corporations Respond to Changes in the Regulatory Environment?,"
Chapters, in: Alistair McGuire & Joan Costa-Font (ed.), The LSE Companion to Health Policy, chapter 12,
Edward Elgar Publishing.
- Varol, Nebibe & Costa-i-Font, Joan & McGuire, Alistair, 2010. "Do international launch strategies of pharmaceutical corporations respond to changes in the regulatory environment?," LSE Research Online Documents on Economics 29972, London School of Economics and Political Science, LSE Library.
- Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
- Kamal Saggi, 2016. "Trade, Intellectual Property Rights, and the World Trade Organization," Vanderbilt University Department of Economics Working Papers 16-00014, Vanderbilt University Department of Economics.
- Charles Courtemanche & James Marton & Benjamin Ukert & Aaron Yelowitz & Daniela Zapata, 2018.
"Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self‐Assessed Health,"
Southern Economic Journal, John Wiley & Sons, vol. 84(3), pages 660-691, January.
- Courtemanche, Charles & Marton, James & Ukert, Benjamin & Yelowitz, Aaron & Zapata, Daniela, 2017. "Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self-Assessed Health," IZA Discussion Papers 10649, Institute of Labor Economics (IZA).
- Charles Courtemanche & James Marton & Benjamin Ukert & Aaron Yelowitz & Daniela Zapata, 2017. "Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self-Assessed Health," NBER Working Papers 23269, National Bureau of Economic Research, Inc.
- Innocenti, Federico & McCormick, Barry & Nicodemo, Catia, 2025. "Gatekeeping in primary care: Analysing GP referral patterns and specialist consultations in the NHS," Economic Modelling, Elsevier, vol. 142(C).
- Amitabh Chandra & Amy Finkelstein & Adam Sacarny & Chad Syverson, 2016.
"Health Care Exceptionalism? Performance and Allocation in the US Health Care Sector,"
American Economic Review, American Economic Association, vol. 106(8), pages 2110-2144, August.
- Amitabh Chandra & Amy Finkelstein & Adam Sacarny & Chad Syverson, 2015. "Healthcare Exceptionalism? Performance and Allocation in the U.S. Healthcare Sector," NBER Working Papers 21603, National Bureau of Economic Research, Inc.
- Chandra, Amitabh & Finkelstein, Amy & Sacarny, Adam & Syverson, Chad, 2015. "Healthcare Exceptionalism? Performance and Allocation in the U.S. Healthcare Sector," Working Paper Series 15-058, Harvard University, John F. Kennedy School of Government.
- Anil Aswani & Zuo-Jun Max Shen & Auyon Siddiq, 2019. "Data-Driven Incentive Design in the Medicare Shared Savings Program," Operations Research, INFORMS, vol. 67(4), pages 1002-1026, July.
- Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
- Eric W. Bond & Kamal Saggi, 2023.
"Compulsory licensing, price controls, and access to patented foreign products,"
World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 19, pages 437-448,
World Scientific Publishing Co. Pte. Ltd..
- Bond, Eric W. & Saggi, Kamal, 2014. "Compulsory licensing, price controls, and access to patented foreign products," Journal of Development Economics, Elsevier, vol. 109(C), pages 217-228.
- Eric Saggi & Saggi Saggi, 2012. "Compulsory licensing, price controls, and access to patented foreign products," Vanderbilt University Department of Economics Working Papers 12-00006, Vanderbilt University Department of Economics.
- Tomaso Duso & Annika Herr & Moritz Suppliet, 2014.
"The Welfare Impact Of Parallel Imports: A Structural Approach Applied To The German Market For Oral Anti‐Diabetics,"
Health Economics, John Wiley & Sons, Ltd., vol. 23(9), pages 1036-1057, September.
- Duso, T. & Herr, A. & Suppliet, M, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-diabetics," Health, Econometrics and Data Group (HEDG) Working Papers 14/09, HEDG, c/o Department of Economics, University of York.
- Tomaso Duso & Annika Herr & Moritz Suppliet, 2014. "The Welfare Impact of Parallel Imports: A Structural Approach Applied to the German Market for Oral Anti-Diabetics," Discussion Papers of DIW Berlin 1373, DIW Berlin, German Institute for Economic Research.
- Duso, Tomaso & Herr, Annika & Suppliet, Moritz, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral anti-diabetics," DICE Discussion Papers 137, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
- Suppliet, Moritz & Duso, Tomaso & Herr, Annika, 2014. "The welfare impact of parallel imports: A structural approach applied to the German market for oral antidiabetics," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100298, Verein für Socialpolitik / German Economic Association.
- Eric Nauenberg, 2014. "Changing healthcare capital-to-labor ratios: evidence and implications for bending the cost curve in Canada and beyond," International Journal of Health Economics and Management, Springer, vol. 14(4), pages 339-353, December.
- Eric Nauenberg, 2014. "Changing Healthcare Capital-To-Labor Ratios: Evidence and Implications for Bending the Cost Curve in Canada and Beyond," Working Papers 140002, Canadian Centre for Health Economics, revised Jul 2014.
- Brandyn F. Churchill & Laura E. Henkhaus & Emily C. Lawler, 2025. "Effect of vaccine recommendations on consumer and firm behavior," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 44(1), pages 125-150, January.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011.
"External referencing and pharmaceutical price negotiation,"
Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2008. "External referencing and pharmaceutical price negotiation," Working Papers 0815, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00303682, HAL.
- Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2010. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00955856, HAL.
- Jagrič, Timotej & Brown, Christine & Boyce, Tammy & Jagrič, Vita, 2021. "The impact of the health-care sector on national economies in selected European countries," Health Policy, Elsevier, vol. 125(1), pages 90-97.
- Ajay Bhaskarabhatla & Priyatam Anurag & Chirantan Chatterjee & Enrico Pennings, 2021. "How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry," Strategy Science, INFORMS, vol. 6(3), pages 209-227, September.
- Craig, Stuart V. & Ericson, Keith Marzilli & Starc, Amanda, 2021. "How important is price variation between health insurers?," Journal of Health Economics, Elsevier, vol. 77(C).
- Milan Zafirovski, 2022. "Some dilemmas of economic democracy: Indicators and empirical analysis," Economic and Industrial Democracy, Department of Economic History, Uppsala University, Sweden, vol. 43(1), pages 252-302, February.
- Margaret K. Kyle, 2018.
"Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets,"
Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 211-234, August.
- Margaret Kyle, 2016. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Working Papers hal-01448521, HAL.
- Margaret Kyle, 2018. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Post-Print hal-01952663, HAL.
- Margaret Kyle, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," Working Papers hal-01952727, HAL.
- Kyle, Margaret, 2017. "Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets," CEPR Discussion Papers 12420, C.E.P.R. Discussion Papers.
- Heidi L. Williams, 2016.
"Intellectual Property Rights and Innovation: Evidence from Health Care Markets,"
Innovation Policy and the Economy, University of Chicago Press, vol. 16(1), pages 53-87.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Chapters, in: Innovation Policy and the Economy, Volume 16, pages 53-87, National Bureau of Economic Research, Inc.
- Heidi L. Williams, 2015. "Intellectual Property Rights and Innovation: Evidence from Health Care Markets," NBER Working Papers 21246, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:aea:aecrev:v:107:y:2017:i:5:p:486-90. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Michael P. Albert (email available below). General contact details of provider: https://edirc.repec.org/data/aeaaaea.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.
Printed from https://ideas.repec.org/a/aea/aecrev/v107y2017i5p486-90.html